DNKO
Katherine Hammer is an accomplished professional with extensive experience in data analytics, business intelligence, and leadership in technology-driven environments. Currently serving as Co-Founder and CEO of DNKO since July 2023, Katherine focuses on advancing cancer treatments for underserved populations, particularly through innovative clinical trials for recurrent Glioblastoma. As a Board Member at OurBrainBank since December 2022, Katherine contributes to strategic initiatives in cancer research. Previously, Katherine held significant roles including Senior Director of Data Analytics at JobGet, where expertise in analytics, hiring, and operations was demonstrated, and Director of Analytics at Omaze, where team growth and business intelligence tooling were prioritized. Prior experience includes positions at LinkedIn, AdColony, Ellucian, CSAA Insurance Group, Cuyahoga Community College, and OEConnection, showcasing a strong foundation in project management, data infrastructure, and analytics leadership. Katherine earned a Bachelor of Science in Business Administration with a focus on Economics from Florida Southern College.
This person is not in any teams
DNKO
As children of parents who had cancer we have experienced how devastating the disease can be. We both shifted how we utilize our life for our work to be dedicated to improving the standard of care for patients. DNKO LLC is a collaboration between David Needham PhD, DSc and Katherine Onk. Vision Our overall DNKO vision is that brain cancer patients will have access to a clinically more effective treatment that prioritizes patients before profits and, when tested, may even be curative for the right sized and LITT-heatable tumors. Mission Our current DNKO mission is to bring existing and proven technology, specifically Laser Interstitial Thermal Therapy (LITT) and David's invention, the Low Temperature Sensitive Liposomal Doxorubicin (LTSL-Dox) to the brain cancer community, uniting like-minded clinicians to evaluate it, test it and (if it shows promise) bring it as soon as possible to their patients.